Posted by Michael Wonder on 25 May 2021
Dupixent (dupilumab) now publicly reimbursed in Ontario and New Brunswick for the treatment of moderate to severe atopic dermatitis
25 May 2021 - Dupixent is the only biologic medicine approved by Health Canada to treat moderate to severe atopic dermatitis.
Sanofi Canada is pleased to announce that Ontario and New Brunswick have listed Dupixent (dupilumab) on their respective provincial drug programs for the treatment of moderate-to-severe atopic dermatitis for Canadians aged 12 years and older when specific criteria are met.
